These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 32849597

  • 21. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2016 Nov 01; 90(21):10022-10038. PubMed ID: 27581977
    [Abstract] [Full Text] [Related]

  • 22. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.
    Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW.
    MAbs; 2018 Apr 01; 10(3):453-462. PubMed ID: 29553863
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors.
    van Mechelen L, Luytjes W, de Haan CA, Wicht O.
    Antiviral Res; 2016 Aug 01; 132():1-5. PubMed ID: 27185625
    [Abstract] [Full Text] [Related]

  • 27. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE.
    J Virol; 2004 Aug 01; 78(16):8446-54. PubMed ID: 15280453
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC, McAuliffe JM, Murphy BR, Collins PL.
    J Virol; 2001 May 01; 75(10):4594-603. PubMed ID: 11312329
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M.
    J Exp Med; 1998 Aug 17; 188(4):681-8. PubMed ID: 9705950
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease.
    Spender LC, Hussell T, Openshaw PJ.
    J Gen Virol; 1998 Jul 17; 79 ( Pt 7)():1751-8. PubMed ID: 9680139
    [Abstract] [Full Text] [Related]

  • 37. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS.
    J Infect Dis; 1999 Oct 17; 180(4):1324-7. PubMed ID: 10479165
    [Abstract] [Full Text] [Related]

  • 38. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
    Fuentes S, Arenas D, Moore MM, Golding H, Khurana S.
    Vaccine; 2017 Jan 23; 35(4):694-702. PubMed ID: 27989627
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T.
    Antimicrob Agents Chemother; 2015 Dec 14; 60(3):1264-73. PubMed ID: 26666922
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.